Daniel P. Mould

629 total citations
8 papers, 440 citations indexed

About

Daniel P. Mould is a scholar working on Molecular Biology, Hematology and Immunology. According to data from OpenAlex, Daniel P. Mould has authored 8 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 2 papers in Hematology and 2 papers in Immunology. Recurrent topics in Daniel P. Mould's work include Epigenetics and DNA Methylation (6 papers), Histone Deacetylase Inhibitors Research (5 papers) and Cancer therapeutics and mechanisms (2 papers). Daniel P. Mould is often cited by papers focused on Epigenetics and DNA Methylation (6 papers), Histone Deacetylase Inhibitors Research (5 papers) and Cancer therapeutics and mechanisms (2 papers). Daniel P. Mould collaborates with scholars based in United Kingdom. Daniel P. Mould's co-authors include Allan M. Jordan, Alison E. McGonagle, Daniel H. Wiseman, Emma L. Williams, James R. Hitchin, Donald Ogilvie, Tim C. P. Somervaille, Alba Maiqués-Díaz, Gary J. Spencer and Emma Fairweather and has published in prestigious journals such as Journal of Medicinal Chemistry, Cell Reports and Medicinal Research Reviews.

In The Last Decade

Daniel P. Mould

8 papers receiving 437 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel P. Mould United Kingdom	8	388	62	54	51	33	8	440
George Lund United Kingdom	7	247 0.6×	54 0.9×	52 1.0×	38 0.7×	12 0.4×	12	367
Mauro Romanenghi Italy	7	346 0.9×	71 1.1×	26 0.5×	29 0.6×	32 1.0×	8	395
Michelle R. Cronk United States	6	327 0.8×	88 1.4×	49 0.9×	74 1.5×	10 0.3×	7	417
Christina R. Majer United States	9	688 1.8×	39 0.6×	69 1.3×	87 1.7×	20 0.6×	13	797
Kazushi Araki Japan	12	264 0.7×	57 0.9×	25 0.5×	49 1.0×	17 0.5×	24	379
Terry D. Crawford United States	7	256 0.7×	73 1.2×	37 0.7×	61 1.2×	11 0.3×	8	325
Matthew Lindon United Kingdom	9	292 0.8×	107 1.7×	80 1.5×	58 1.1×	18 0.5×	11	393
Cindy Palmer United States	8	158 0.4×	57 0.9×	67 1.2×	40 0.8×	28 0.8×	10	275
Giulia Stazi Italy	14	423 1.1×	13 0.2×	77 1.4×	50 1.0×	56 1.7×	16	517
David K. Miyamoto United States	8	320 0.8×	24 0.4×	110 2.0×	85 1.7×	14 0.4×	9	406

Countries citing papers authored by Daniel P. Mould

Since Specialization

Citations

This map shows the geographic impact of Daniel P. Mould's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel P. Mould with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel P. Mould more than expected).

Fields of papers citing papers by Daniel P. Mould

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel P. Mould. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel P. Mould. The network helps show where Daniel P. Mould may publish in the future.

Co-authorship network of co-authors of Daniel P. Mould

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel P. Mould. A scholar is included among the top collaborators of Daniel P. Mould based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel P. Mould. Daniel P. Mould is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Maiqués-Díaz, Alba, Gary J. Spencer, James T. Lynch, et al.. (2018). Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia. Cell Reports. 22(13). 3641–3659. 137 indexed citations

Waszkowycz, Bohdan, Kate M. Smith, Alison E. McGonagle, et al.. (2018). Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides. Journal of Medicinal Chemistry. 61(23). 10767–10792. 26 indexed citations

Mould, Daniel P., Ulf Bremberg, Allan M. Jordan, et al.. (2017). Development of 5-hydroxypyrazole derivatives as reversible inhibitors of lysine specific demethylase 1. Bioorganic & Medicinal Chemistry Letters. 27(14). 3190–3195. 13 indexed citations

Mould, Daniel P., Ulf Bremberg, Allan M. Jordan, et al.. (2017). Development and evaluation of 4-(pyrrolidin-3-yl)benzonitrile derivatives as inhibitors of lysine specific demethylase 1. Bioorganic & Medicinal Chemistry Letters. 27(20). 4755–4759. 10 indexed citations

Mould, Daniel P., Cristina Alli, Ulf Bremberg, et al.. (2017). Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1. Journal of Medicinal Chemistry. 60(19). 7984–7999. 41 indexed citations

Mould, Daniel P., Alison E. McGonagle, Daniel H. Wiseman, Emma L. Williams, & Allan M. Jordan. (2014). Reversible Inhibitors of LSD1 as Therapeutic Agents in Acute Myeloid Leukemia: Clinical Significance and Progress to Date. Medicinal Research Reviews. 35(3). 586–618. 108 indexed citations

Raoof, Ali, Paul Depledge, Niall M. Hamilton, et al.. (2013). Toxoflavins and Deazaflavins as the First Reported Selective Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase II. Journal of Medicinal Chemistry. 56(16). 6352–6370. 55 indexed citations

Hitchin, James R., Julian Blagg, Rosemary Burke, et al.. (2013). Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments. MedChemComm. 4(11). 1513–1513. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact